Key result
Intraluminal delivery of gliadin peptide p31-43 induced morphological changes, cell death, and inflammatory mediator expression in normal mice via MyD88 and type I IFNs.
Why the study?
Does intraluminal delivery of gliadin peptide p31-43 induce innate immune activation and morphological changes in the small intestinal mucosa of normal mice?
Does intraluminal delivery of gliadin peptide p31-43 induce innate immune activation and morphological changes in the small intestinal mucosa of normal mice?
Gliadin peptide p31-43 activates innate immune pathways in vivo, suggesting a mechanism for the interaction between dietary gluten and viral infections in celiac disease pathogenesis.
Does not support targeting p31-43 in celiac disease; leaves open its innate immune role pending human validation.
Celiac disease (CD) is an immune-mediated enteropathy triggered by gluten in genetically susceptible individuals. Innate immunity contributes to the pathogenesis of CD, but the mechanisms remain poorly understood. Although previous in vitro work suggests that gliadin peptide p31-43 acts as an innate immune trigger, the underlying pathways are unclear and have not been explored in vivo. Here we show that intraluminal delivery of p31-43 induces morphological changes in the small intestinal mucosa of normal mice consistent with those seen in CD, including increased cell death and expression of inflammatory mediators. The effects of p31-43 were dependent on MyD88 and type I IFNs, but not Toll-like receptor 4 (TLR4), and were enhanced by coadministration of the TLR3 agonist polyinosinic:polycytidylic acid. Together, these results indicate that gliadin peptide p31-43 activates the innate immune pathways in vivo, such as IFN-dependent inflammation, relevant to CD. Our findings also suggest a common mechanism for the potential interaction between dietary gluten and viral infections in the pathogenesis of CD.
No takes yet. Share an insight, caveat, or question.
Araya et al. (2016) studied Celiac disease. Intraluminal delivery of gliadin peptide p31-43 was evaluated on Morphological changes in the small intestinal mucosa, cell death, and expression of inflammatory mediators. Intraluminal delivery of gliadin peptide p31-43 induced morphological changes, cell death, and inflammatory mediator expression in normal mice via MyD88 and type I IFNs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: